Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $80.88M
- EPS (TTM)
- -$1.27
- Dividend yield
- None
- 52-week range
- 1.50 – 7.51
- Day range
- 1.62 – 2.01
- Volume / Avg
- 1.20M / 261.88K
- Beta
- —
- Shares outstanding
- 41.05M
52-week range
IMDX stock today
On Nov 20, IMDX ended the session at $1.97, adding $0.31 (18.67%), versus the S&P 500's 3.70% decline. Volume was 4.6x the average at 1.20M shares, a sign of unusually heavy trading. At this level, IMDX sits near the bottom of its 52-week range of $1.50 to $7.51: 73.8% below the high, set on Dec 31, 2025 and 31.3% above the low.
IMDX is down 73.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.4%. Insight Molecular Diagnostics has posted a net loss over the last twelve months (EPS of -$1.27), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Insight Molecular Diagnostics
Company profileInsight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Joshua Riggs
- Headquarters
- Nashville, TN
- Employees
- 55
- Website
- imdxinc.com
Financial highlights
Full financialsIn fiscal 2025, Insight Molecular Diagnostics generated $4.1 million in revenue, up 115.6% from fiscal 2024, its 3rd consecutive year of revenue growth. Insight Molecular Diagnostics reported a net loss of $50.2 million, compared with a loss of $60.7 million a year earlier. Gross margin was 56.7% (up from 39.3%) and operating margin -1260.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.05M | $1.88M | $1.50M | $958.00K | $2.20M |
| Growth | +115.58% | +25.15% | +56.89% | -56.41% | +80.76% |
| Net income | $-50.22M | $-60.66M | $-27.78M | $-72.90M | $-64.10M |
| EPS (diluted) | $-1.65 | $-4.66 | $-3.75 | $-13.25 | $-0.72 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$8.25+318.78%
- Strong buy 1
- Buy 2
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.34 vs —
IMDX news
All IMDX news- Healthcare Stocks In Focus - ITOC +17%, EVAX +13%, IMDX +10%; AKAN And EVH See Trading ActivityNasdaqAKAN, EVAX, EVH, IMDX
- iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry StudyGlobeNewswire
- Biotech Stocks Move Higher - VIVS +120%, POAS +29%, INSM +19%, ICU +7%, IMDX +9%NasdaqICU, IMDX, INSM, POAS
- Insight Molecular Diagnostics Inc. Announces Pricing of $15 Million Public OfferingNasdaq
- Insight Molecular (IMDX) Q3 2026 Earnings Call TranscriptNasdaq
- IMDx Reports Third Quarter 2026 Results and Provides Corporate UpdateGlobeNewswire
- Insight Molecular Diagnostics Announces Proposed Public OfferingGlobeNewswire
- iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx LaunchGlobeNewswire
Insight Molecular Diagnostics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs IMDX |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs IMDX |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs IMDX |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs IMDX |
| BMRABiomerica Inc. | 1.08 | -0.92% | $4.97M | vs IMDX |
| CDIOCardio Diagnostics Holdings Inc. | 1.60 | -3.03% | $4.74M | vs IMDX |
| QCLSQ/C Technologies Inc. | 0.2784 | -6.01% | $2.40M | vs IMDX |
| VRAXVirax Biolabs Group Limited | 0.3319 | -12.89% | $446.40K | vs IMDX |
Indexes, lists and sector
Insight Molecular Diagnostics stock FAQ
What is Insight Molecular Diagnostics's stock price today?
IMDX last traded at $1.97 as of Nov 20, 4:00 PM EST, up 18.67% on the day. Prices are delayed at least 15 minutes.
Does Insight Molecular Diagnostics pay a dividend?
No. Insight Molecular Diagnostics does not currently pay a regular cash dividend.
Who is Insight Molecular Diagnostics's CEO?
Mr. Joshua Riggs is the chief executive officer of Insight Molecular Diagnostics Inc., which has about 55 employees.
Has IMDX ever split its stock?
Yes. The most recent IMDX stock split was a 1-for-20 split on Jul 25, 2023.
What is the IMDX 52-week high?
The 52-week high for IMDX is $7.51 and the 52-week low is $1.50. The stock is currently 73.8% below its high.